PMS-BENZYDAMINE MOUTHWASH/GARGLE

Country: Կանադա

language: անգլերեն

source: Health Canada

buyitnow

SPC SPC (SPC)
26-10-2017

active_ingredient:

BENZYDAMINE HYDROCHLORIDE

MAH:

PHARMASCIENCE INC

ATC_code:

A01AD02

INN:

BENZYDAMINE

dosage:

0.15%

pharmaceutical_form:

MOUTHWASH/GARGLE

composition:

BENZYDAMINE HYDROCHLORIDE 0.15%

administration_route:

BUCCAL

units_in_package:

100ML/250ML

prescription_type:

Prescription

therapeutic_area:

MOUTHWASHES AND GARGLES

leaflet_short:

Active ingredient group (AIG) number: 0113801001; AHFS:

authorization_status:

APPROVED

authorization_date:

1999-01-25

SPC

                                PRODUCT MONOGRAPH
PR
PMS-BENZYDAMINE
Benzydamine Mouthwash, BP
Benzydamine Hydrochloride 1.5 mg/mL (0.15% w/v)
LOCAL ANALGESIC
PHARMASCIENCE INC.
6111 Royalmount Avenue Suite #100
Montreal, QC, CANADA, H4P 2T4
www.pharmascience.com
Date of Preparation:
October 26, 2017
Submission Control No: 210244
_Product Monograph pms-BENZYDAMINE Page 2 of 13_
TABLE OF CONTENTS
PART I: HEALTH PROFESSIONAL INFORMATION
........................................................ 3
SUMMARY PRODUCT INFORMATION
........................................................................
3
INDICATIONS AND CLINICAL USE
..............................................................................
3
CONTRAINDICATIONS
...................................................................................................
3
WARNINGS AND PRECAUTIONS
.................................................................................
3
DOSAGE AND ADMINISTRATION
................................................................................
4
OVERDOSAGE
..................................................................................................................
4
ACTION AND CLINICAL PHARMACOLOGY
.............................................................. 4
STORAGE AND STABILITY
...........................................................................................
5
DOSAGE FORMS, COMPOSITION AND PACKAGING
............................................... 5
PART II: SCIENTIFIC INFORMATION
.................................................................................
6
PHARMACEUTICAL INFORMATION
...........................................................................
6
CLINICAL TRIALS
............................................................................................................
7
DETAILED PHARMACOLOGY
.......................................................................................
7
TOXICOLOGY
...................................................................................................................
7
REFERENCES
                                
                                read_full_document
                                
                            

documents_in_other_languages

SPC SPC ֆրանսերեն 26-10-2017